149 research outputs found

    Directions for the future of technology in pronunciation research and teaching

    Get PDF
    This paper reports on the role of technology in state-of-the-art pronunciation research and instruction, and makes concrete suggestions for future developments. The point of departure for this contribution is that the goal of second language (L2) pronunciation research and teaching should be enhanced comprehensibility and intelligibility as opposed to native-likeness. Three main areas are covered here. We begin with a presentation of advanced uses of pronunciation technology in research with a special focus on the expertise required to carry out even small-scale investigations. Next, we discuss the nature of data in pronunciation research, pointing to ways in which future work can build on advances in corpus research and crowdsourcing. Finally, we consider how these insights pave the way for researchers and developers working to create research-informed, computer-assisted pronunciation teaching resources. We conclude with predictions for future developments

    Automatic Assessment of Speech Capability Loss in Disordered Speech

    Get PDF
    International audienceIn this article, we report on the use of an automatic technique to assess pronunciation in the context of several types of speech disorders. Even if such tools already exist, they are more widely used in a different context, namely, Computer-Assisted Language Learning, in which the objective is to assess nonnative pronunciation by detecting learners' mispronunciations at segmental and/or suprasegmental levels. In our work, we sought to determine if the Goodness of Pronunciation (GOP) algorithm, which aims to detect phone-level mispronunciations by means of automatic speech recognition, could also detect segmental deviances in disordered speech. Our main experiment is an analysis of speech from people with unilateral facial palsy. This pathology may impact the realization of certain phonemes such as bilabial plosives and sibilants. Speech read by 32 speakers at four different clinical severity grades was automatically aligned and GOP scores were computed for each phone realization. The highest scores, which indicate large dissimilarities with standard phone realizations, were obtained for the most severely impaired speakers. The corresponding speech subset was manually transcribed at phone level; 8.3% of the phones differed from standard pronunciations extracted from our lexicon. The GOP technique allowed the detection of 70.2% of mispronunciations with an equal rate of about 30% of false rejections and false acceptances. Finally, to broaden the scope of the study, we explored the correlation between GOP values and speech comprehensibility scores on a second corpus, composed of sentences recorded by six people with speech impairments due to cancer surgery or neurological disorders. Strong correlations were achieved between GOP scores and subjective comprehensibility scores (about 0.7 absolute). Results from both experiments tend to validate the use of GOP to measure speech capability loss, a dimension that could be used as a complement to physiological measures in pathologies causing speech disorders

    Height and timing of growth spurt during puberty in young people living with vertically acquired HIV in Europe and Thailand.

    Get PDF
    OBJECTIVE: The aim of this study was to describe growth during puberty in young people with vertically acquired HIV. DESIGN: Pooled data from 12 paediatric HIV cohorts in Europe and Thailand. METHODS: One thousand and ninety-four children initiating a nonnucleoside reverse transcriptase inhibitor or boosted protease inhibitor based regimen aged 1-10 years were included. Super Imposition by Translation And Rotation (SITAR) models described growth from age 8 years using three parameters (average height, timing and shape of the growth spurt), dependent on age and height-for-age z-score (HAZ) (WHO references) at antiretroviral therapy (ART) initiation. Multivariate regression explored characteristics associated with these three parameters. RESULTS: At ART initiation, median age and HAZ was 6.4 [interquartile range (IQR): 2.8, 9.0] years and -1.2 (IQR: -2.3 to -0.2), respectively. Median follow-up was 9.1 (IQR: 6.9, 11.4) years. In girls, older age and lower HAZ at ART initiation were independently associated with a growth spurt which occurred 0.41 (95% confidence interval 0.20-0.62) years later in children starting ART age 6 to 10 years compared with 1 to 2 years and 1.50 (1.21-1.78) years later in those starting with HAZ less than -3 compared with HAZ at least -1. Later growth spurts in girls resulted in continued height growth into later adolescence. In boys starting ART with HAZ less than -1, growth spurts were later in children starting ART in the oldest age group, but for HAZ at least -1, there was no association with age. Girls and boys who initiated ART with HAZ at least -1 maintained a similar height to the WHO reference mean. CONCLUSION: Stunting at ART initiation was associated with later growth spurts in girls. Children with HAZ at least -1 at ART initiation grew in height at the level expected in HIV negative children of a comparable age

    Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>The prevalence of depression in patients with acute coronary syndrome, i.e. myocardial infarction and unstable angina, is higher than in the general population. The prevalence of anxiety is higher as well. Both depression and anxiety are associated with poor cardiac outcomes and higher mortality. Comorbid depression in patients with acute coronary syndrome often goes undiagnosed, and it is therefore a challenging task to prevent this risk factor. The study of DEpression in Coronary ARtery Disease (DECARD) is designed to examine if it is possible to prevent depression in patients with acute coronary syndrome.</p> <p>Methods</p> <p>Two hundred forty non-depressed patients with acute coronary syndrome are randomized to treatment with either escitalopram or placebo for 1 year. Psychiatric and cardiac assessment of patients is performed to evaluate the possibility of preventing depression. Diagnosis of depression and Hamilton Depression Scale are the primary outcome measures.</p> <p>Discussion</p> <p>This is the first study of prevention of depression in patients after acute coronary syndrome with a selective serotonin reuptake inhibitor.</p> <p>Trial Registration</p> <p><url>http://www.ClinicalTrials.gov.</url> Identifier: NCT00140257</p

    Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients

    Get PDF
    Background: To date, standardized strategies for the treatment of recurrent glioma are lacking. Chemotherapy with the alkylating agent BCNU (1,3-bis (2-chloroethyl)-1-nitroso-urea) is a therapeutic option even though its efficacy and safety, particularly the risk of pulmonary fibrosis, remains controversial. To address these issues, we performed a retrospective analysis on clinical outcome and side effects of BCNU-based chemotherapy in recurrent glioma. Methods: Survival data of 34 mostly chemotherapy-naïve glioblastoma patients treated with BCNU at 1st relapse were compared to 29 untreated control patients, employing a multiple Cox regression model which considered known prognostic factors including MGMT promoter hypermethylation. Additionally, medical records of 163 patients treated with BCNU for recurrent glioma WHO grade II to IV were retrospectively evaluated for BCNU-related side effects classified according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 2.0. Results: In recurrent glioblastoma, multiple regression survival analysis revealed a significant benefit of BCNU-based chemotherapy on survival after relapse (p = 0.02; HR = 0.48; 95 % CI = 0.26–0.89) independent of known clinical and molecular prognostic factors. Exploratory analyses suggested that survival benefit was most pronounced in MGMT-hypermethylated, BCNU-treated patients. Moreover, BCNU was well tolerated by 46 % of the 163 patients analyzed for side effects; otherwise, predominantly mild side effects occurred (CTCAE I/II; 45 %). Severe side effects CTCAE III/IV were observed in 9 % of patients including severe hematotoxicity, thromboembolism, intracranial hemorrhage and injection site reaction requiring surgical intervention. One patient presented with a clinically apparent pulmonary fibrosis CTCAE IV requiring temporary mechanical ventilation. Conclusion: In this study, BCNU was rarely associated with severe side effects, particularly pulmonary toxicity, and, in case of recurrent glioblastoma, even conferred a favorable outcome. Therefore BCNU appears to be an appropriate alternative to other nitrosoureas although the efficacy against newer drugs needs further evaluation
    corecore